These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 21835825)

  • 21. A phase I trial of oxaliplatin in combination with docetaxel in patients with advanced solid tumors.
    Iqbal S; Lenz HJ; Gandara DR; Shibata SI; Groshen S; Synold TW; Newman EM
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):85-91. PubMed ID: 23712328
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I and pharmacokinetic study of lapatinib and docetaxel in patients with advanced cancer.
    LoRusso PM; Jones SF; Koch KM; Arya N; Fleming RA; Loftiss J; Pandite L; Gadgeel S; Weber BL; Burris HA
    J Clin Oncol; 2008 Jun; 26(18):3051-6. PubMed ID: 18565892
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase I pharmacological and biological study of PI-88 and docetaxel in patients with advanced malignancies.
    Chow LQ; Gustafson DL; O'Bryant CL; Gore L; Basche M; Holden SN; Morrow MC; Grolnic S; Creese BR; Roberts KL; Davis K; Addison R; Eckhardt SG
    Cancer Chemother Pharmacol; 2008 Dec; 63(1):65-74. PubMed ID: 18320191
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Docetaxel in combination with gemcitabine plus rhG-CSF support as second-line treatment in non-small cell lung cancer. A multicenter phase II study.
    Kakolyris S; Papadakis E; Tsiafaki X; Kalofonos C; Rapti A; Toubis M; Bania E; Kouroussis C; Chainis K; Androulakis N; Agelaki S; Sarra E; Vardakis N; Georgoulias V;
    Lung Cancer; 2001 May; 32(2):179-87. PubMed ID: 11325489
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I trial of non-cytotoxic suramin as a modulator of docetaxel and gemcitabine therapy in previously treated patients with non-small cell lung cancer.
    Lam ET; Au JL; Otterson GA; Guillaume Wientjes M; Chen L; Shen T; Wei Y; Li X; Bekaii-Saab T; Murgo AJ; Jensen RR; Grever M; Villalona-Calero MA
    Cancer Chemother Pharmacol; 2010 Nov; 66(6):1019-29. PubMed ID: 20107799
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase II study of escalated-dose docetaxel with granulocyte colony-stimulating factor support in patients with advanced breast cancer.
    Mitchell PL; Basser R; Chipman M; Grigg A; Mansfield R; Cebon J; Davis ID; Appia F; Green M
    Ann Oncol; 2004 Apr; 15(4):585-9. PubMed ID: 15033663
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and tolerability of selumetinib as a monotherapy, or in combination with docetaxel as second-line therapy, in Japanese patients with advanced solid malignancies or non-small cell lung cancer.
    Seto T; Hirai F; Saka H; Kogure Y; Yoh K; Niho S; Fukase K; Shimada H; Sasai M; Fukino K
    Jpn J Clin Oncol; 2018 Jan; 48(1):31-42. PubMed ID: 29136201
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I trial of pegylated liposomal doxorubicin and docetaxel in advanced breast cancer.
    Sparano JA; Malik U; Rajdev L; Sarta C; Hopkins U; Wolff AC
    J Clin Oncol; 2001 Jun; 19(12):3117-25. PubMed ID: 11408509
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Multicenter Study of Docetaxel at a Dose of 100 mg/m
    Hirata T; Ozaki S; Tabata M; Iwamoto T; Hinotsu S; Hamada A; Motoki T; Nogami T; Shien T; Taira N; Matsuoka J; Doihara H
    Intern Med; 2021 Apr; 60(8):1183-1190. PubMed ID: 33191320
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/DMXAA) 1800mg/m(2) combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer.
    McKeage MJ; Reck M; Jameson MB; Rosenthal MA; Gibbs D; Mainwaring PN; Freitag L; Sullivan R; Von Pawel J
    Lung Cancer; 2009 Aug; 65(2):192-7. PubMed ID: 19409645
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial.
    Seddon B; Strauss SJ; Whelan J; Leahy M; Woll PJ; Cowie F; Rothermundt C; Wood Z; Benson C; Ali N; Marples M; Veal GJ; Jamieson D; Küver K; Tirabosco R; Forsyth S; Nash S; Dehbi HM; Beare S
    Lancet Oncol; 2017 Oct; 18(10):1397-1410. PubMed ID: 28882536
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase 1 dose escalation and pharmacokinetic evaluation of oral gemcitabine prodrug (LY2334737) in combination with docetaxel in patients with advanced solid tumors.
    Salazar R; Morales S; Gil-Martín M; Aguirre E; Oaknin A; Garcia M; Callies S; Wickremsinhe ER; Benhadji KA; Llombart A
    Cancer Chemother Pharmacol; 2014 Jun; 73(6):1205-15. PubMed ID: 24744161
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Phase I/II clinical trial of weekly administration of docetaxel plus cisplatin for advanced non-small cell lung cancer].
    Li JL; Zhang XR; Liu JW; Chen ZY; Lin YC; Wang YD; Chen Q; Nan KJ; Song SP; Han FC; Zhu YZ; Li LY; Zheng YH; Chu DT
    Zhonghua Zhong Liu Za Zhi; 2006 Apr; 28(4):309-12. PubMed ID: 16875636
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase I and pharmacokinetic study of docetaxel administered in combination with continuous intravenous infusion of 5-fluorouracil in patients with advanced solid tumors.
    Van Den Neste E; de Valeriola D; Kerger J; Bleiberg H; Kusenda Z; Brassinne C; Bartholomeus S; Selleslags J; Hennebert P; Wythouck H; Cazenave I; Lefresne-Soulas F; Piccart M
    Clin Cancer Res; 2000 Jan; 6(1):64-71. PubMed ID: 10656433
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The efficacy and safety of reduced-dose docetaxel, cisplatin, and 5-fluorouracil in the first-line treatment of advanced stage gastric adenocarcinoma.
    Ozdemir NY; Abali H; Oksüzoğlu B; Budakoglu B; Uncu D; Güler T; Odabaşi H; Zengin N
    Med Oncol; 2010 Sep; 27(3):680-4. PubMed ID: 19633962
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A multicenter phase II study of docetaxel, oxaliplatin, and bevacizumab in first-line therapy for unresectable locally advanced or metastatic non-squamous cell histology non-small-cell lung cancer (NSCLC).
    Raez LE; Santos ES; Webb RT; Wade J; Brito RA; Karr M; Kennah A; Childs BH
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):1103-10. PubMed ID: 24057043
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A dose escalation study of weekly docetaxel in patients with advanced solid tumors.
    Kouroussis C; Agelaki S; Mavroudis D; Souglakos J; Kakolyris S; Kalbakis K; Vardakis N; Reppa D; Hatzidaki D; Samonis G; Georgoulias V
    Cancer Chemother Pharmacol; 2000; 46(6):488-92. PubMed ID: 11138462
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A dose-escalation study of pemetrexed and docetaxel in non-small-cell lung cancer.
    Kotsakis A; Agelaki S; Vardakis N; Stathopoulos G; Vamvakas L; Kalykaki A; Kentepozidis N; Kontopodis E; Sfakiotaki G; Mavroudis D; Georgoulias V
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):415-22. PubMed ID: 21069335
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A phase I study of bi-weekly docetaxel for recurrent or advanced gastric cancer patients whose disease progressed by prior chemotherapy.
    Kimura Y; Yano H; Taniguchi H; Iwazawa T; Danno K; Kagara N; Kanoh T; Ohnishi T; Tono T; Nakano Y; Monden T; Imaoka S
    Jpn J Clin Oncol; 2011 Jun; 41(6):747-51. PubMed ID: 21498408
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Feasibility re-evaluation of 75 mg/m² docetaxel in Japanese patients with previously treated non-small cell lung cancer.
    Yamada K; Takeoka H; Mizoguchi Y; Yamashita F; Yoshida T; Zaizen Y; Okayama Y; Naito Y; Azuma K; Hoshino T
    Jpn J Clin Oncol; 2014 Apr; 44(4):338-45. PubMed ID: 24482414
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.